Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Goldman Sachs: Expects the US Dollar to Continue Its Decline Against Asian Currencies

Goldman Sachs: Expects the US Dollar to Continue Its Decline Against Asian Currencies

金色财经金色财经2025/05/14 00:47
Show original

According to a report by Jinse Finance, Goldman Sachs stated that after recent progress in trade negotiations, the likely direction for the USD/Asian currency pair remains downward. It noted that despite recent progress in trade negotiations between China and the United States, the main themes in the market have not changed. These themes are: the trend of gradually diversifying investments away from U.S. assets is expected to continue; Asian exporters are likely to keep converting dollars into local currencies; if the Asian region engages in trade negotiations with the United States, currency depreciation may become more difficult. (Jin10)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

华尔街见闻•2026/10/26 05:56
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.